Cephalon Inc. (CEPH) is in the Health Care Industry

• Sort by

• Acusphere Announces Signing of a Definitive Agreement with Cephalon

  WATERTOWN, Mass. -- Acusphere, Inc. (NASDAQ:ACUS) today announced the signing of a definitive agreement with Cephalon, Inc. to provide $20 million in upfront financing by purchasing a $15 million senior secured convertible note and by paying a $5 million upfront fee for an exclusive worldwide license to AI-525, a preclinical-stage...

  Research articles 2008-10-25

  Tags: agreement, Cephalon Inc., Company, FDA, FINANCE, Government, Nasdaq Stock Market Inc., Readers

• Cephalon, Inc. Conference Call to Discuss the Proceedings at the FDA Advisory Committee - Research and Markets Offers a Brief of 'Cephalon, Inc.' Conference Call

  DUBLIN, Ireland -- The Cephalon, Inc. (NASDAQ:CEPH) Corporate Conference Call took place on 23-Mar-06 6:00pm ET.

  Research articles 2006-03-23

  Tags: advisory committee, Cephalon Inc., FDA

• FDA Issues Approvable Letter for VIVITROL™ , for the Treatment of Alcohol Dependence; Alkermes and Cephalon Continue to Anticipate Product Launch in Second Quarter 2006

  CAMBRIDGE, Mass.& FRAZER, Pa. -- Alkermes, Inc. (Nasdaq: ALKS) and Cephalon, Inc. (Nasdaq: CEPH) today announced that the U.S. Food and Drug Administration FDA issued an approvable letter for VIVITROLTM (naltrexone for extended-release injectable suspension), which is under review for the treatment of alcohol dependence in combination with a treatment...

  Research articles 2005-12-28

  Tags: Cephalon Inc., FDA

• FDA Extends PDUFA Date for VIVITREX® to December 30, 2005; Cephalon and Alkermes Continue to Anticipate VIVITREX Launch in First Half of 2006

  FRAZER, Pa. & CAMBRIDGE, Mass. -- Cephalon, Inc. (Nasdaq: CEPH) and Alkermes, Inc. (Nasdaq: ALKS) announced today that they have received notification from the United States Food and Drug Administration FDA that the agency has extended the action date to December 30, 2005 for its priority review of the New...

  Research articles 2005-09-20

  Tags: Cephalon Inc., FDA

• Cephalon Wins FDA Approval to Sell Narcolepsy Drug to Treat Sleep Disorders.

  By Linda Loyd, The Philadelphia Inquirer Knight Ridder/Tribune Business News By Linda Loyd, The Philadelphia Inquirer Knight Ridder/Tribune Business News

  Research articles 2004-01-27

  Tags: Cephalon Inc., FDA

• FDA Panel Backs Cephalon's Drug to Treat Some Sleep Disorders.

  By Linda Loyd, The Philadelphia Inquirer Knight Ridder/Tribune Business News By Linda Loyd, The Philadelphia Inquirer Knight Ridder/Tribune Business News

  Research articles 2003-09-26

  Tags: Cephalon Inc., FDA

• Cephalon to Ask FDA to Widen Use of Sleep-Disorder Drug.

  By Linda Loyd, The Philadelphia Inquirer Knight Ridder/Tribune Business News By Linda Loyd, The Philadelphia Inquirer Knight Ridder/Tribune Business News

  Research articles 2003-09-25

  Tags: Cephalon Inc., FDA

• Cephalon and Chiron Announce Plan to Submit NDA for Myotrophin to FDA

  WEST CHESTER, Pa. and EMERYVILLE, Calif.--BUSINESS WIRE--April 16, 1996--Cephalon Inc. (NASDAQ:CEPH) and its partner, Chiron Corporation (NASDAQ:CHIR), announced today that, following discussions with the U.S. Food and Drug Administration FDA, the two companies will submit a New Drug Application NDA to market MyotrophinR (rhIGF-1) for the treatment of amyotrophic lateral...

  Research articles 1996-04-16

  Tags: Cephalon Inc., Chiron Corp., FDA

Additional Resources

• Fda Approves Cephalon Treanda To Treat Non-Hodgkins Lymphoma

  Cephalon, Inc., (Nasdaq: CEPH) has announced that the U.S. Food and Drug Administration FDA has approved TREANDAr bendamustine hydrochloride for Injection for the treatment of patients with indolent B-cell non- Hodgkin's lymphoma NHL that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. The...

  Articles 2008-12-01

• Cephalon Added to S&P 500 Today

  FRAZER, Pa., Nov. 14 /PRNewswire-FirstCall/ -- Cephalon, Inc., today announced that Standard and Poor's will add Cephalon to the S&P 500 Index after the close of trading on Friday, November 14. Cephalon has been listed in the S&P MidCap 400 Index. "We are honored to...

  Articles 2008-11-14

• Zacks Analyst Blog Highlights: Companhia Energetica de Minas Gerais, SurModics, Inc., Acusphere, Inc., Cephalon, Inc. and drugstore.com

  CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Companhia Energetica de Minas Gerais (NYSE: CIG), SurModics, Inc. (Nasdaq: SRDX),...

  Articles 2008-11-12

• Standard & Poor's Announces Changes to U.S. Indices

  NEW YORK, Nov. 11 /PRNewswire/ -- Standard & Poor's will make the following changes to the S&P 500 and S&P MidCap 400 indices: -- General Growth Properties Inc. (NYSE Arca: GGP) will be removed from the S&P 500 after the close...

  Articles 2008-11-11

• Zacks Analyst Blog Highlights: Sprint Nextel Corp., Ultrapar Participacoes SA, Eurand N.V., Cephalon, Inc. and GlaxoSmithKline Inc

  CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Sprint Nextel Corp. (NYSE: S), Ultrapar Participa[?][?]es SA (NYSE: UGP), Eurand...

  Articles 2008-11-11

• Acusphere, Inc. Reports Q3 2008 Financial Results and Business Highlights

  WATERTOWN, Mass. -- Acusphere, Inc. (NASDAQ: ACUS) today reported financial results for the third quarter ended September 30, 2008 and commented on its financial results and business highlights. Recent Developments Following the close of the third quarter, Acusphere announced a definitive agreement with Cephalon, Inc. to...

  Articles 2008-11-10

• Zacks Analyst Interview Highlights: Acusphere and Cephalon

  CHICAGO -- Zacks.com releases the latest Analyst Interview. Today's interview is with senior analyst Jason Napodano, who discusses Acusphere (Nasdaq: ACUS) and Cephalon (Nasdaq: CEPH). Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=2678. Any recent news...

  Articles 2008-11-03

• Video: Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin's Lymphoma

  TREANDA Receives Second Indication this Year; Data Demonstrate High, Durable Response Rates for Patients with indolent NHL Who Have Progressed Following a Rituximab-Containing Regimen FRAZER, Pa., Nov. 3 /PRNewswire-FirstCall/ -- Cephalon, Inc., today announced that the U.S. Food and Drug Administration FDA has approved TREANDAR (bendamustine...

  Articles 2008-11-03

• Acusphere Announces Closing of Transaction with Cephalon

  WATERTOWN, Mass. -- Acusphere, Inc. (NASDAQ: ACUS) today announced that it closed its previously announced transaction with Cephalon, Inc., which will provide Acusphere with $20 million in immediate financing through the issuance of a $15 million senior secured convertible note and a $5 million upfront fee for an exclusive worldwide...

  Articles 2008-11-03

• Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin's Lymphoma

  TREANDA Receives Second Indication this Year; Data Demonstrate High, Durable Response Rates for Patients with indolent NHL Who Have Progressed Following a Rituximab-Containing Regimen FRAZER, Pa., Oct. 31 /PRNewswire-FirstCall/ -- Cephalon, Inc., today announced that the U.S. Food and Drug Administration FDA has approved TREANDAR (bendamustine...

  Articles 2008-10-31

• Cephalon, Inc. to Webcast Analyst Day

  FRAZER, Pa., Oct. 30 /PRNewswire-FirstCall/ -- Cephalon, Inc. today announced that its Analyst Day in New York City, to be held on November 5, 2008, will be webcast live on the investor relations section of its website at http://www.cephalon.com/. Cephalon's senior management will review the company's...

  Articles 2008-10-30

• Cephalon Reports Another Strong Quarter

  Record Sales of $490 Million, Up 14 Percent over Third Quarter 2007 Company Raises Full Year 2008 Sales and Earnings Guidance Introduces 2009 Adjusted Net Income Guidance, Up 27 Percent over 2008 FRAZER, Pa., Oct. 28 /PRNewswire-FirstCall/ -- Cephalon, Inc. today reported...

  Articles 2008-10-28